Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, Kanellopoulos J, Martin F, Rébé C, Apetoh L, Ghiringhelli F. Bruchard M, et al. Among authors: derangere v. Nat Med. 2013 Jan;19(1):57-64. doi: 10.1038/nm.2999. Epub 2012 Dec 2. Nat Med. 2013. PMID: 23202296
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.
Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, Ladoire S, Derangère V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, Rébé C, Ghiringhelli F. Chalmin F, et al. Among authors: derangere v. Immunity. 2012 Mar 23;36(3):362-73. doi: 10.1016/j.immuni.2011.12.019. Epub 2012 Mar 8. Immunity. 2012. PMID: 22406269
Knock-down of the oxysterol receptor LXRα impairs cholesterol efflux in human primary macrophages: lack of compensation by LXRβ activation.
Ishibashi M, Filomenko R, Rébé C, Chevriaux A, Varin A, Derangère V, Bessède G, Gambert P, Lagrost L, Masson D. Ishibashi M, et al. Among authors: derangere v. Biochem Pharmacol. 2013 Jul 1;86(1):122-9. doi: 10.1016/j.bcp.2012.12.024. Epub 2013 Jan 9. Biochem Pharmacol. 2013. PMID: 23313547
SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growth.
Berger H, Végran F, Chikh M, Gilardi F, Ladoire S, Bugaut H, Mignot G, Chalmin F, Bruchard M, Derangère V, Chevriaux A, Rébé C, Ryffel B, Pot C, Hichami A, Desvergne B, Ghiringhelli F, Apetoh L. Berger H, et al. Among authors: derangere v. Cancer Res. 2013 Jun 15;73(12):3578-90. doi: 10.1158/0008-5472.CAN-12-4018. Epub 2013 Apr 25. Cancer Res. 2013. PMID: 23619236
Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.
Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, Ladoire S, Chalmin F, Végran F, Rébé C, Apetoh L, Ghiringhelli F, Mignot G. Bugaut H, et al. Among authors: derangere v. PLoS One. 2013 Jun 7;8(6):e65181. doi: 10.1371/journal.pone.0065181. Print 2013. PLoS One. 2013. PMID: 23762310 Free PMC article.
The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells.
Végran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, Chalmin F, Rébé C, Dérangère V, Ryffel B, Kato M, Prévost-Blondel A, Ghiringhelli F, Apetoh L. Végran F, et al. Among authors: derangere v. Nat Immunol. 2014 Aug;15(8):758-66. doi: 10.1038/ni.2925. Epub 2014 Jun 29. Nat Immunol. 2014. PMID: 24973819
Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells.
Derangère V, Chevriaux A, Courtaut F, Bruchard M, Berger H, Chalmin F, Causse SZ, Limagne E, Végran F, Ladoire S, Simon B, Boireau W, Hichami A, Apetoh L, Mignot G, Ghiringhelli F, Rébé C. Derangère V, et al. Cell Death Differ. 2014 Dec;21(12):1914-24. doi: 10.1038/cdd.2014.117. Epub 2014 Aug 15. Cell Death Differ. 2014. PMID: 25124554 Free PMC article.
The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.
Bruchard M, Rebé C, Derangère V, Togbé D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Végran F, Ghiringhelli F. Bruchard M, et al. Among authors: derangere v. Nat Immunol. 2015 Aug;16(8):859-70. doi: 10.1038/ni.3202. Epub 2015 Jun 22. Nat Immunol. 2015. PMID: 26098997
Liver X receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization.
Courtaut F, Derangère V, Chevriaux A, Ladoire S, Cotte AK, Arnould L, Boidot R, Rialland M, Ghiringhelli F, Rébé C. Courtaut F, et al. Among authors: derangere v. Oncotarget. 2015 Sep 29;6(29):26651-62. doi: 10.18632/oncotarget.5791. Oncotarget. 2015. PMID: 26450852 Free PMC article.
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F. Derangère V, et al. Oncotarget. 2016 Feb 23;7(8):9309-21. doi: 10.18632/oncotarget.7008. Oncotarget. 2016. PMID: 26824184 Free PMC article.
40 results
Jump to page
Feedback